Special Issue "Next Generation Histone Deacetylase (HDAC) Inhibitors"
Deadline for manuscript submissions: 31 January 2019
Prof. Dr. Thomas Kurz
Heinrich-Heine-Universität Düsseldorf, Institute for Pharmaceutical and Medicinal Chemistry, Universitätsstraße 1, 40225 Düsseldorf, Germany
Website | E-Mail
Interests: anti-infective drug discovery; epigenetic drug discovery; metalloenzyme inhibitors; protein-protein interactions; multi-target drugs
Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for the treatment of cancer. Thus far, four histone deacetylase inhibitors (HDACi) have been approved by the FDA to combat certain types of lymphoma or multiple myeloma. Furthermore, there is growing evidence that HDACi have therapeutic potential in several diseases beyond cancer, such as inflammation, HIV, and parasitic and neurodegenerative diseases. First-generation inhibitors are non-selective HDACi that target multiple isoforms which might lead to serious side effect. In the field of cancer, it is currently under debate whether class- or isoform-selective HDACi can provide improved risk-benefit profiles compared to first-generation pan-inhibitors. In the field of non-oncology diseases, it is evident that the use of pan-HDACi is limited due to their side effects. Thus, there is a strong need for new HDACi with optimized selectivity profiles.
The aim of this Special Issue is to highlight recent efforts in the design, synthesis, and pharmacological evaluation of next-generation histone deacetylase inhibitors. We welcome original articles and short communications as well as review articles.
Prof. Dr. Thomas Kurz
Prof. Dr. Finn K. Hansen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- HDAC inhibitors
- drug design
- chromatin modification
- chemical probe and assay development